Adaptation to living with cardiovascular disease may differ from patient to patient and is influenced not only by disease severity and limitations incurred by the disease but also by socioeconomic factors (e.g. health literacy), the patients' psychological make-up and susceptibility to distress. Co-morbid depression and/or anxiety is prevalent in 20% of patients with cardiovascular disease, which may be either transient or chronic. Distress, such as depression, reduces adherence, serves as a barrier to behaviour change and the adoption of a healthy lifestyle, and increases the risk that patients drop out of cardiac rehabilitation, impacting on patients' quality of life, risk of hospitalisation and mortality. Hence it is paramount to identify this subset of high-risk patients in clinical practice. This review provides a general overview of the prevalence of selected psychosocial risk factors, their impact on patient-reported and clinical outcomes, and biological and behavioural mechanisms that may explain the association between psychosocial factors and health outcomes. The review also provides recommendations on which self-report screening measures to use to identify patients at high risk due to their psychosocial profile, and the effectiveness of available trials that target these risk factors. Despite challenges and barriers associated with screening of patients combined with appropriate treatment, it is paramount that we treat not only the heart but also the mind in order to improve the quality of care and patient and clinical outcomes.
Introduction
Considerable knowledge on the role of psychosocial risk factors in cardiovascular disease (CVD) has been accumulated during the past 30 years. The aim of this state-of-the-art review is to provide an overview of the main psychosocial risk factors, their prevalence and association with patient and clinical outcomes, mechanisms that may explain these associations, and how to target these factors in clinical practice.
is between 15% and 20% in CVDs and clinically relevant depressive symptom estimates are much higher. 1, 2 Depression is especially deleterious to cardiovascular prognosis post-myocardial infarction (MI). 1 There does not appear to be a meaningful difference in prognosis for persons with pre-existing depression or those developing depression post-MI, 3 suggesting both subtypes are equally important. Anxiety is investigated to a lesser extent than depression in CVD populations, but a recent meta-analysis indicated a 16% prevalence rate of anxiety disorders, 4 although individual disorder prevalence varies markedly (Table 1 ). Among the anxiety disorders, evidence implicates generalised anxiety disorder with poorer CVD prognosis in a recent metaanalysis. 4 
Positive emotions
Positive emotions appear to benefit cardiovascular prognosis. An exploratory meta-analysis on positive emotions (e.g. positive affect, optimism) indicated a reduced rate of rehospitalisation and mortality in adjusted analyses (odds ratio (OR) 0.88; 95% confidence interval (CI) 0.84-0.91; P < 0.001). 5 
Stress
In the broadest sense, stress encompasses mental and environmental stress, posttraumatic stress and low perceived social support. Empirical work on stress in CVD reveals associations with adverse CVD prognosis, regardless of the definition of stress studied. A wealth of literature supports that low social support portends MACE risk. 6 Findings for posttraumatic stress and acute coronary syndrome (ACS) prognosis have emerged more recently and appear to signify higher mortality and MACE risk. 7 Personality A longstanding body of work has investigated personality traits in CVDs. Recent studies with contemporary conceptualisations of personality traits implicate hostility and anger with adverse CVD prognosis. 8 Another conceptualisation of personality traits known as Type D personality is defined as the co-occurrence of negative affectivity and social inhibition. A recent review of 12 studies 9 corroborated an association between Type D personality with hard endpoints such as MACE and death (adjusted hazard ratio (HR) of 2.24 (95% CI 1.37-3.66). In summary, collective findings demonstrate that depression, other negative emotions, stress and personality factors are associated with MACE risk, whereas positive emotions appear to be associated with better CVD prognosis.
Biological and behavioural pathways linking psychosocial risk factors to CVD Risk for incident CVD
A meta-analysis of large-scale population-based studies of apparently healthy individuals shows that psychosocial factors, such as depression, anxiety, anger/hostility, social isolation/low social support, chronic stress, and posttraumatic stress disorder (PTSD) are associated with an approximate 1.5-fold excess risk of incident cardiovascular events, including ACS and death. 10 The direction of this relationship rules out reverse causality, supporting the status of psychosocial factors as causal risk factors for CVD. A long-term follow-up study in 1,107,524 young Swedish men supports this notion. 11 In spite of abundant statistical adjustments for various sociodemographic and CVD risk factors, residual confounding by unmeasured common causes remains a possible explanation in these prospective observational studies. 12 As an example, epigenetic programming of a hyperactive stress response system in utero in offspring of stressed mothers may carry over to adulthood. As a consequence of such biographical/ epigenetic and environmental antecedents, autonomic, neuroendocrine and immune system dysfunction facilitates both atherosclerosis progression 12 and, as part of the sickness response, signalling of negative affect and social withdrawal to the brain through an interoceptive route many years before CVD events occur. 13, 14 Moreover, congruent with the concept of allostasis, sustained adaptive changes in the cardiovascular system to taxing environmental ('stressful') situations lead to allostatic load and overload in the form of cardiometabolic and structural arterial changes; the resulting endothelial dysfunction, subclinical atherosclerosis, overt CVD and poor prognosis reflect the long-term cardiovascular costs of adaptation to stress. To sum up the above reasoning, it is likely that some individuals experience low psychological wellbeing and feelings of distress many years before the clinical manifestation of CVD. In turn, cardiac events may provoke profound psychological and acute phase reactions, from which incident psychosocial risk factors may arise, like depression, anxiety and PTSD. 15, 16 Biological and behavioural pathways Figure 1 illustrates that psychosocial factors impact on cardiovascular health by different pathways and mechanisms, many of which are linked with each other. Newly emerging, but also pre-existent psychosocial factors that persist in the wake of a cardiac event, such as personality characteristics or job stress, affect atherosclerosis development and progression through behavioural and biological pathways. 16 Psychosocial factors are associated with altered hypothalamic pituitary adrenal axis function, increased output of the sympathetic nervous system, and parasympathetic/vagal withdrawal. Against a background of endothelial dysfunction, chronic alterations in these central outputs induce distinct pathophysiological responses, as summarised in Table 2 . 17 Low-grade inflammation and coagulation activation play particularly important roles, as they facilitate growth, vulnerability and haemodynamically induced erosion/rupture of an atherosclerotic plaque with thrombotic coronary occlusion. 18 As shown in Figure 2 , the latter is a key mechanism in the biology of emotionally triggered ACS, such as with outbursts of anger. 19 Psychosocial factors and stress are associated with more adverse lifestyle behaviours related to smoking, physical activity, diet, alcohol consumption and sleep health. 16 Further consequences of psychosocial factors are non-adherence with medication, poor consultation behaviour and low attendance in cardiac rehabilitation. 16 Stress-related health behaviours and biological mechanisms additionally contribute to the development of modifiable traditional cardiometabolic risk factors, including high blood pressure and hypertension, dyslipidaemia and high cholesterol, insulin sensitivity and type 2 diabetes, as well as weight gain and increased body mass index. 12 In a vicious cycle, traditional cardiovascular risk factors (e.g. obesity and diabetes) and secondary complications (e.g. physical immobility and peripheral arterial disease) act in concert with psychosocial factors as profound barriers to lifestyle change (e.g. starting a regular exercise programme). 16 
Implications for clinical research and practice
The patient perspective Patient-reported outcomes, such as symptoms, perceived health status and quality of life, represent powerful measures to inform clinicians, patients and professional societies, 20 and may influence the uptake of these outcomes in clinical research and practice. 21 Importantly, psychosocial risk factors such as depression, anxiety, Type D personality and perceived social isolation may significantly contribute to poorer perceived health status, quality of life and other important patient-reported outcomes. 16 For example, a metaanalysis of prospective studies in various cardiovascular patient groups showed that Type D personality was associated with a more than 2-fold increased odds for impaired physical and mental health status. 22 Cardiologists and other health professionals should be aware of these substantial individual differences in patient-reported outcomes in order to identify highrisk patients and improve their perceived health status.
Effects of interventions targeting psychosocial risk factors
Psychotropic medication, cognitive-behavioural therapy and psychotherapy all address psychosocial risk factors but evidence for a beneficial effect on cardiac prognosis is inconclusive. 16 A number of clinical trials have examined the effect of treating depression in patients with CVD. 23 Overall, these trials only showed reductions in depressive symptoms that are not clinically significant, and could not show that depression treatment decreased the risk of (recurrent) cardiac events or improved health status in cardiac patients. 23, 24 However, these studies yielded a number of important insights that may enhance the effectiveness of future interventions.
First, secondary analyses of these depression trials suggest that cardiac prognosis improves when the intervention is effective in improving depression. 23 Second, evidence suggests that cardiac rehabilitation should Flow-mediated dilation#, nitric oxide production and bioavailability#, endothelin-1", von Willebrand factor" Proinflammatory state C-reactive protein", interleukin-6", tumour necrosis factor-a", interleukin-1b", anti-inflammatory cytokines# (IL-4, IL-10), white blood cell count", cellular adhesion molecules" Prothrombotic state Fibrinogen and other clotting factors", fibrin D-dimer", plasminogen activator inhibitor-1", platelet activity" also integrate counselling for psychosocial risk factors, 16 as the combination of cardiac rehabilitation and stress management training seems to produce greater reductions in anxiety, distress and stress levels than cardiac rehabilitation alone. 25 Third, intervention trials need to take into account the moderating effects of sample and patient characteristics and should also be targeted to the individual patient's needs and preferences. A meta-analysis suggests that depression treatment may be more useful in coronary artery bypass graft patients, while anxiety treatment may be particularly useful in patients with an implantable cardioverter defibrillator. 26 A recent trial in depressed patients with CVD found a significant treatment-by-Type D interaction on change in depression, suggesting that psychotherapy might be beneficial for depressed patients with Type D personality but not for non-Type D patients. 27 Concerted efforts are needed to develop more effective psychosocial interventions, based on better insights into biobehavioural mechanisms of stress-related disease and the identification of high-risk subgroups. 23 Until such interventions are available, at the individual patient level, it is important to continue to refer patients with clinically significant levels of distress for specialised psychopharmacological or psychological treatment, due to the impact of distress on adherence, participation in cardiac rehabilitation, lifestyle changes and patient-reported and clinical outcomes. 16, 28, 29 
Recognition of psychosocial risk factors in clinical practice
In order to help patients at high risk due to their psychosocial profile, it is paramount that we are able to identify this subset. Although the evidence for screening protocols making a difference to patient outcomes is scarce and barriers for implementation plentiful, the alternative of doing nothing with the knowledge that depression is a treatable condition seems unacceptable. 30 A selection of psychosocial measures used to screen and identify at-risk patients in a cardiac setting is presented in Table 3 . These include the patient health questionnaire (PHQ) 2 and 9 that have been recommended by the American Heart Association. 31 
Emotional stress
Activation of sympathetic nervous system with catecholamine surge All measures are generic and available in several languages. Although disease-specific measures are available for specific subsets of patients (e.g. the ICD Patients Concerns Questionnaire (ICDC) 32 and the Cardiac Anxiety Questionnaire (CAQ), 33 etc.), it is beyond the scope of this paper to provide an exhaustive list.
Recommendations and future perspectives
Focus on psychosocial factors in the European Society of Cardiology Textbook of Cardiovascular Medicine in 2009 34 and the European guidelines on CVD prevention in clinical practice in 2012 35 have paved the way for more research in the field of cardiac psychology/ behavioural cardiology and a greater understanding of the role of psychosocial factors in cardiovascular health. However, we are still far from treating the body and mind together. In order to advance the field and enhance the quality of care for patients with CVD we need to:
. Implement screening of patients in clinical practice in order to identify the subset of patients at risk. We have core questions available for the physicians to include in their interview 36 and full, standardised and validated questionnaires [37] [38] [39] [40] [41] to make a more extended assessment that has been shown to predict patient and clinical outcomes. . Start incorporating psychosocial factors into CVD risk prediction models at an equal level to standard risk factors, such as age and smoking, as psychosocial factors are not only risk modifiers but also independent risk factors for poor patient and clinical outcomes. 36 . Design effective interventions that target psychosocial risk factors and that use a more precision medicine approach rather than a 'one-size-fits-all' approach. This warrants that we gain a better understanding of individual patients' needs and preferences but also knowledge about barriers and facilitators of their implementation in clinical practice. . Start treating body and mind together, as successful risk factor management at the patient level has a large behavioural component. Hence we need to strive for more integrated care in general but also in the cardiac rehabilitation setting. In cardiac rehabilitation, physical training, setting goals for risk factor management, psycho-education and psychosocial intervention should be integrated, while also taking into account the patient's context (e.g. family, health literacy and other vulnerability factors). This requires that we work together in an integrated fashion across disciplines placing the patient centre stage. 
